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ABSTRACT
Hypersensitivity myocarditis is a rare but serious adverse effect of clozapine, a commonly used psychiatric drug. We report 
the case of sudden cardiac death from clozapine-induced hypersensitivity myocarditis diagnosed at autopsy. A 54-year-old 
Caucasian male on clozapine therapy for bipolar disorder presented with a sudden onset of shortness of breath. Laboratory 
studies were significant for elevated N-terminal prohormone of brain natriuretic peptide. During his hospital stay, the 
patient died of sudden cardiac arrest from ventricular tachycardia. The autopsy revealed hypersensitivity myocarditis, which 
usually occurs in the first 4 weeks after the initiation of clozapine. A 4-week monitoring protocol, including laboratory 
assessment of troponin and C-reactive protein, may assist in the early diagnosis of this potentially fatal condition. 
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INTRODUCTION
Clozapine, a newer atypical antipsychotic, is 
often considered as the gold standard therapy in the 
management of treatment-resistant schizophrenia,1 
and has often been used off-label for the treatment 
of bipolar disorder.2 It is associated with minor adverse 
effects, such as sedation, weight gain, constipation, 
urinary incontinence, and severe adverse effects, such 
as agranulocytosis and seizures.3 Also, clozapine has 
been associated with an underreported but serious 
condition known as clozapine-induced hypersensitivity 
myocarditis (CIHSM).4-7 Although there are few 
reported cases of in vivo diagnosis and successful 
treatment,8-10 unfortunately CIHSM is often diagnosed 
only by histological examination of an autopsied 
heart specimen as it can potentially cause sudden 
cardiac death (SCD). Awareness of this condition, 
and understanding the clinical clues and diagnostic 
methods, may help in the early diagnosis of CIHSM 
and enable appropriate intervention to prevent SCD.
CASE REPORT
The patient was a 54-year-old Caucasian male 
with a history of anxiety, bipolar disorder, and chronic 
kidney disease (CKD) stage III secondary to hypertensive 
nephrosclerosis. He was referred to our facility for the 
evaluation of shortness of breath and tachycardia. 
The patient attributed his shortness of breath to 
anxiety. He denied any chest pain or palpitations. There 
was no history of orthopnea, paroxysmal nocturnal 
dyspnea, or lower limb swelling. His vital signs showed 
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a regular heart rate of 110 bpm, a respiratory rate of 
20/min, and blood pressure of 118/78 mmHg. He was 
afebrile and had peripheral capillary oxygen saturation 
of 96% on room air. Jugular venous pressure was 
normal. For the past 6 weeks he had been treated with 
clozapine for his psychiatric illness.
An electrocardiogram showed sinus tachycardia 
with nonspecific ST-T wave changes. The chest 
radiograph was unremarkable. Troponin T (Tn-T) 
was normal  at  < 0.01 ng/mL (normal  range 
[NR]: < 0.01 ng/mL), but N-terminal prohormone of 
brain natriuretic peptide (NT-proBNP) was elevated 
at 750 pg/mL (NR: 0.0-125.0 pg/mL) and D-Dimer 
was elevated at 3.1 mcg/mL (NR: 0.00-0.50 mcg/mL). 
A complete blood count with differential was normal 
with a normal eosinophil count. The serum chemistry 
was s ign i f icant  for  c reat in ine of  1 .6 mg/dL 
(NR: 0.67-1.17 mg/dL), which was unchanged from 
the baseline. A chest radiograph showed minimal 
lineal bibasilar atelectasis. A ventilation perfusion scan 
was performed, which suggested low probability for 
pulmonary embolism. There was no evidence of deep 
venous thrombosis on venous ultrasound of the lower 
limbs. Transthoracic echocardiogram revealed normal 
left ventricular systolic function (the ejection fraction 
was calculated at 57.7% using the Teicholz formula) 
with mild diastolic dysfunction.
On the third day of admission, the patient 
sustained sudden cardiac arrest due to pulseless 
ventricular tachycardia. An autopsy of the heart was 
performed for transplant purposes, excluding other 
body parts, as per the family request. The pre-dissection 
weight of the heart was 319 g (NR: 338–589 g). 
All four chambers were normal in size. All four valves 
leaflets were thin, delicate, and freely movable without 
vegetation. Sections of the coronary arteries were 
free of significant atherosclerotic disease. No acute 
intraluminal coronary thrombus was seen. The sections 
of the right atrial wall revealed normal sinoatrial node. 
Histological examination of myocardial sections showed 
patchy perivascular mixed inflammation with some 
associated fibrosis (Figure 1A). There were histiocytes, 
lymphocytes, and neutrophils, as well as eosinophils 
with interstitial inflammation (Figure 1B). There was no 
significant myocyte damage. The  diagnosis of CIHSM 
was made and was attributed as the cause of SCD.
DISCUSSION
Clozapine,  a l though commonly used for 
treatment-resistant schizophrenia, is occasionally 
used as an off-label indication for bipolar disorder.1,2 
Neutropenia and seizures are well-reported serious 
adverse effects of clozapine.3 CIHSM, a drug-related 
myocarditis, is an under-reported severe condition.4-7
Hypersensitivity myocarditis is the most common 
form of drug-induced myocardial disease, among others, 
such as toxic myocarditis, endocardial fibrosis (caused 
by medications such as fenfluramine, ergotamine 
tartrate, phentermine, methysergide), drug-induced 
cardiomyopathy (caused by medications such as 
Figure 1. Photomicrography of the myocardium. A - A “roadmap” pattern of perivascular mixed inflammation 
with eosinophils (arrow) (H&E, 100X); B - Higher power view of the perivascular inflammation showing small round 
lymphocytes, histiocytes, and eosinophils with bilobed nuclei (arrow) (H&E, 400X).
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anthracycline, chloroquine), and giant cell myocarditis.11 
Several medications, including clozapine, sulfonamides, 
penicillin, methyldopa, furosemide, tetracycline, 
azithromycin, aminophylline, and phenytoin are 
associated with hypersensitivity myocarditis.12-14 
The pathological process of hypersensitivity myocarditis 
comprises an eosinophilic infiltration of the myocardium; 
therefore, it is considered as a sub-type of eosinophilic 
myocarditis.11,15 Eosinophilic myocarditis is frequently 
associated with systemic hypereosinophilic conditions, 
such as hypereosinophilic syndrome, Churg-Strauss 
syndrome, and parasitic infections that have a high 
peripheral eosinophil count, as well as patients awaiting 
cardiac transplant who are on intravenous inotropic 
agents.11,15,16 In contrast, the peripheral eosinophil 
count is often normal in hypersensitivity myocarditis; 
therefore, it is not useful for a diagnosis. In our patient, 
parasitic infections and hypereosinophilic systemic 
diseases were considered less likely as he had a normal 
peripheral eosinophil count.
Kilian et al.5 first described the association between 
clozapine and myocarditis in 1999. The reported 
incidence of CIHSM is widely variable. A 2007 
retrospective analysis study of 116 cases in Australia 
reported an incidence between 0.7% and 1.2% of all 
clozapine treated cases.4 The incidence of myocarditis 
in some studies was noted to be as high as 8.5%.6 
Since many patients are either undiagnosed or 
unreported, it is challenging to assess the accurate 
incidence of CIHSM.
Several studies have suggested a wide range of 
onset times of CIHSM symptoms after the initiation of 
clozapine. While cases have been reported as early as 
16 days after the initiation of the drug,4 up to 75% 
of the patients develop symptoms within the first 
month,17 85% cases within the first two months,17 and 
a few cases may develop symptoms up to 2 years later.4
Initial presenting symptoms of CIHSM can be 
nonspecific flu-like symptoms, such as malaise, fatigue, 
pleuritic chest pain, cough, and rash, and may be evident 
as a clinical sign of hypersensitivity.11 Sinus tachycardia 
is one of the early clinical signs detected in 90% of 
the CIHSM cases.18 Clozapine may induce autonomic 
imbalance, decreased parasympathetic tone, and 
increased sympathetic drive; in so doing, it can cause 
resting tachycardia.19 Although the exact mechanism 
of CIHSM is unclear, increased circulating plasma 
catecholamine from a high sympathetic drive could be 
responsible for triggering an inflammatory response 
resulting in myocarditis; therefore, beta-adrenergic 
blockade may reduce the incidence and the severity.20 
Wang20 illustrated that clozapine-treated mice had a 
substantial increase in myocardial inflammation that 
correlated with higher plasma catecholamine levels, 
and that subsequent blockade of beta-adrenergic 
receptors with propranolol significantly attenuated 
these effects.20 During hospitalization, our patient had 
persistent sinus tachycardia with a heart rate ranging 
from 110 bpm to 140 bpm, which reduced to 101 bpm 
with the use of metoprolol.
Further diagnostic clues may emanate from 
measuring cardiac troponin, NT-proBNP, and C-reactive 
protein (CRP) as they are often elevated in CIHSM. 
In a case control study conducted in Australia, 
Ronaldson et al.7 showed that 90% of the diagnosed 
CIHSM cases had elevated troponins within 4 weeks of 
starting clozapine; whereas CRP was elevated in 70% 
of these cases. However, in five cases where Tn-T was 
normal, CRP was elevated. The study also suggested 
that a combination of CRP (> 100 mg/L) and cardiac 
troponin (> 2 upper limit normal) had 100% sensitivity 
in identifying CIHSM.18 Based on these results, 
Ronaldson et al.18 proposed a monitoring protocol, 
including periodical assessment of cardiac troponin and 
CRP, during the first 4 weeks of initiation of the drug 
regardless of symptoms. Our patient had normal Tn-T, 
and CRP was not measured. Another cardiac biomarker 
NT-proBNP has been widely used in diagnosing and 
estimating the prognosis of heart failure; however, 
its role in myocarditis has not been well studied. 
Since our patient had elevated NT-proBNP, we believe 
further studies are warranted to better define its role 
in myocarditis in general, and CIHSM in particular.
An echocardiogram may provide diagnostic 
information with wall motion abnormalities in severe 
CIHSM cases, but in cases of less severe focal disease 
its utility is questionable as the findings may be 
nonspecific. Ronaldson et al.18 reported impaired left 
ventricular function in 66% of their patients diagnosed 
with CHISM; however, they did not specify if it was 
a systolic or a diastolic dysfunction. Our patient had 
normal systolic function with mild diastolic dysfunction, 
which is a common finding in his age group.
Similar to other types of myocarditis, the diagnostic 
modality of choice for CIHSM is cardiac magnetic 
resonance imaging (CMR). The use of T2 weighted 
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images increased the sensitivity to 84% and the 
specificity to 74% in diagnosing myocarditis.21 Contrast 
enhancement with gadolinium has been shown to 
further increase diagnostic accuracy.21,22
Endomyocardial biopsy (EMB) is often considered 
the gold standard test in detecting myocarditis.23 
The 2007 ACC/AHA/ESC/HFSA guidelines recommend 
EMB in cases of suspected hypersensitivity myocarditis.24 
EMB also yields low sensitivity in focal myocarditis. 
CMR has been shown to improve the diagnostic yield 
of EMB by aiding targeted area biopsy.22
Similar to other drug-induced hypersensitivity 
myocarditis, the treatment of CIHSM includes supportive 
management and discontinuation of the drug. 
Significant clinical improvement can be expected in 
patients with myocarditis with intensive hemodynamic 
monitoring and supportive management.25 Although 
the role of corticosteroids is questionable, we did find 
a few published case reports on the beneficial effect 
of steroids in severe cases of myocarditis complicated 
by cardiogenic shock.14,26-28 Also, azathioprine has 
been used as an adjunct in the treatment of patients 
with steroid-resistant hypersensitivity myocarditis and 
cardiogenic shock.29
CONCLUSION
We report the case of CIHSM presenting as 
SCD where the diagnosis was made at autopsy. 
Clozapine-induced hypersensitivity myocarditis is a 
rare and serious condition. A high index of clinical 
suspicion is needed for a timely diagnosis. The vast 
majority of these patients may present with vague 
symptoms or are unable to relay their symptoms. 
Serum cardiac biomarkers and imaging modalities, 
including CMR, can help in the diagnosis of CIHSM. 
Implementing a 4-week monitoring protocol with 
periodical assessment of troponins, after the initiation 
of clozapine, CRP may be a sensitive tool in the early 
diagnosis of this serious adverse reaction.
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